Debt and Interest- Additional Information (Detail) - USD ($)
|
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
|
Sep. 14, 2016 |
Feb. 13, 2014 |
Jan. 31, 2019 |
Sep. 30, 2017 |
Aug. 31, 2017 |
Jul. 31, 2017 |
Jun. 30, 2017 |
May 31, 2017 |
May 02, 2017 |
Mar. 31, 2017 |
Jun. 30, 2016 |
Mar. 31, 2018 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Jun. 26, 2017 |
Dec. 31, 2015 |
Mar. 31, 2015 |
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125,000
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 8.50
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
17.00%
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 900,000
|
|
| Notes Payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 79,503,000
|
$ 62,499,000
|
|
|
|
$ 10,000,000
|
| Debt Instrument, Term |
|
|
|
|
|
|
|
|
|
|
|
|
36 months
|
|
|
|
|
|
|
| Fair Value Adjustment of Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
682,000
|
$ 368,000
|
|
|
|
|
| Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
|
|
|
|
| Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights |
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Legal Fees |
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right Exercise Price Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company .
|
|
|
|
|
| Proceeds from Convertible Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
$ 9,914,000
|
|
|
|
|
| Payments of Financing Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
81,000
|
|
|
|
|
| Debt Instrument Maturity Period Extention Description |
|
|
|
|
|
|
|
|
|
|
|
|
The Company may also use the proceeds to finance its subsidiaries. The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months
|
|
|
|
|
|
|
| Debt Instrument Change in Periodic Interest Payment Description |
|
|
|
|
|
|
|
|
|
|
|
|
Interest on the note is 8% payable quarterly during the first 24 months (or the first 30 months if the note is extended) and monthly during the last 12 months
|
|
|
|
|
|
|
| Development Option and Stock Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value Adjustment of Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
| Commercial Paper [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
|
$ 21,700,000
|
|
|
|
|
|
|
| Subsequent Event [Member] | Common Class B [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Conversion, Converted Instrument, Shares Issued |
|
|
|
1,870,412
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Letter of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
| Letters of Credit Outstanding, Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,100,000
|
|
|
|
|
|
| Israel Discount Bank Of New York [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Current portion of note payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 14,900,000
|
14,900,000
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDB Promissory Note Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
2.25%
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unused Borrowing Capacity, Amount |
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Periodic Payment |
|
|
$ 14,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Opus Credit Facility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
| Warrants and Rights Outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,500,000
|
$ 9,500,000
|
|
|
|
|
| Maturity Date |
|
|
|
|
|
|
|
|
|
|
|
|
|
Sep. 14, 2018
|
|
|
|
|
|
| NSC Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Effective Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.00%
|
|
|
|
|
| Helocyte Convertible Note One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
8.00%
|
|
|
|
|
|
| Debt Instrument, Fee Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
|
|
| Debt Instrument, Maturity Date, Description |
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
December 2017
|
|
|
|
|
|
| Class Of Warrant Or Right Value Of Securities Called By Warrants Or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
|
|
| Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110.00%
|
|
|
|
| Proceeds from Debt, Net of Issuance Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,900,000
|
|
|
|
| Helocyte Convertible Note One [Member] | Conversion One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.
|
|
|
|
| Helocyte Convertible Note One [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
| Helocyte Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Legal Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
| Helocyte Convertible Note [Member] | Conversion One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
|
|
|
|
|
|
|
|
|
the lowest price per share at which equity securities of Helocyte are sold in such sale less a 33% discount and (b) a per share price based on a pre-offering valuation of $50.0 million divided by the number of common shares outstanding on a fully-diluted basis.
|
|
|
|
|
|
|
|
| Helocyte Convertible Note [Member] | Conversion Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Terms of Conversion Feature |
|
|
|
|
|
|
|
|
|
|
|
a discount to the price per share being paid in the Sale of Helocyte equal to 33% or (b) a conversion price per share based on a pre-sale valuation of $50.0 million divided by the fully-diluted common stock of Helocyte immediately prior to the Sale of Helocyte (excluding the notes).
|
|
|
|
|
|
|
|
| Caelum Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class Of Warrant Or Right Exercise Price Percentage Of Warrants Or Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110.00%
|
|
|
|
|
| Class of Warrant or Right Exercise Price Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
the exercise price will be $75 million dollars divided by the total number of fully-diluted shares of Common Stock outstanding immediately prior to exercise of the warrant, giving effect to the assumed conversion of all options, warrants, and convertible securities of the Company.
|
|
|
|
|
| Debt Conversion, Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The notes convert upon a qualified financing in which Caelum raises gross proceeds of at least $10 million as follows: the lesser of (a) a discount to the price per common share being paid in the Sale of the Company equal to 20% or (b) a conversion price per share based on a pre-sale valuation of $75,000,000 divided by the number of common shares outstanding at that time assuming the hypothetical conversion or exercise of any convertible securities, options, warrants and other rights to acquire common shares of the Company.
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
| Debt Instrument Issuance Percentage of Commission |
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
| Proceeds from Convertible Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,900,000
|
|
|
|
|
| Payments of Financing Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 900,000
|
|
|
|
|
| NSC 2017 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
$ 3,250,000
|
|
|
|
|
|
|
|
|
| Debt Instrument, Maturity Date, Description |
|
|
|
|
|
|
|
|
|
|
Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.
|
|
|
Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.
|
|
|
|
|
|
| Paid-in-kind Interest Percentage |
|
|
|
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
| Line of Credit Facility, Current Borrowing Capacity |
|
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
| Warrant on Sale Price of Note Percentage |
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | First Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
|
|
|
87,946
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
|
|
|
|
$ 3.70
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
|
$ 3,200,000
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
|
|
|
|
|
|
300,000
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Secoud Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
|
|
|
$ 3.65
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
$ 8,600,000
|
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
|
|
|
|
|
$ 900,000
|
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Third Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
|
147,806
|
234,438
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
|
|
$ 3.61
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
$ 5,300,000
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Fourth Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
|
|
38,315
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
|
|
$ 4.75
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
$ 1,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Fifth Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
63,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
|
$ 4.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Sixth Closing [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
144,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant exercise price |
|
|
|
|
$ 4.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
$ 6,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Fees Received |
|
|
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 2017 Note [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
$ 40,000,000
|
|
|
|
|
|
|
|
|
| Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
8.00%
|
8.00%
|
|
|
|
|
|
| Debt Instrument, Maturity Date, Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
February - 2021
|
|
|
|
|
|
| DOSPA [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,900,000
|
|
|
|
|
|
| DOSPA [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of Stock, Consideration Received on Transaction |
|
|
|
$ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of Stock Percentage of Shares Transferred on Transaction |
|
|
|
19.90%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC [Member] | Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant on Sale Price of Note Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
25.00%
|
|
|
|
|
|
| Payments of Financing Costs |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,700,000
|
|
|
|
|
|
|
| Class Of Warrant Or Right Expiration Period |
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
| Aevitas Therapeutics Inc [Member] | Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,200,000
|
|
|
|
|
|
| Tamid Bio Inc [Member] | Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
|
|
|
| Cellvation [Member] | Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,100,000
|
|
|
|
|
|
| Cyprium [Member] | Venture Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash proceeds from 2008 Senior Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,700,000
|
|
|
|
|
|
|
|